Regulation of p14<sup>ARF </sup>expression by miR-24: a potential mechanism compromising the p53 response during retinoblastoma development

<p>Abstract</p> <p>Background</p> <p>Most human cancers show inactivation of both pRB- and p53-pathways. While retinoblastomas are initiated by loss of the <it>RB1 </it>tumor suppressor gene, <it>TP53 </it>mutations have not been found. High expr...

Full description

Bibliographic Details
Main Authors: To Kwong-Him, Pajovic Sanja, Gallie Brenda L, Thériault Brigitte L
Format: Article
Language:English
Published: BMC 2012-02-01
Series:BMC Cancer
Online Access:http://www.biomedcentral.com/1471-2407/12/69
Description
Summary:<p>Abstract</p> <p>Background</p> <p>Most human cancers show inactivation of both pRB- and p53-pathways. While retinoblastomas are initiated by loss of the <it>RB1 </it>tumor suppressor gene, <it>TP53 </it>mutations have not been found. High expression of the p53-antagonist MDM2 in human retinoblastomas may compromise p53 tumor surveillance so that <it>TP53 </it>mutations are not selected for in retinoblastoma tumorigenesis. We previously showed that p14<sup>ARF </sup>protein, which activates p53 by inhibiting MDM2, is low in retinoblastomas despite high mRNA expression.</p> <p>Methods</p> <p>In human fetal retinas, adult retinas, and retinoblastoma cells, we determined endogenous <it>p14<sup>ARF </sup></it>mRNA, ARF protein, and miR-24 expression, while integrity of p53 signalling in WERI-Rb1 cells was tested using an adenovirus vector expressing p14<sup>ARF</sup>. To study p14<sup>ARF </sup>biogenesis, retinoblastoma cells were treated with the proteasome inhibitor, MG132, and siRNA against miR-24.</p> <p>Results</p> <p>In human retinoblastoma cell lines, <it>p14<sup>ARF </sup></it>mRNA was disproportionally high relative to the level of p14<sup>ARF </sup>protein expression, suggesting a perturbation of p14<sup>ARF </sup>regulation. When p14<sup>ARF </sup>was over-expressed by an adenovirus vector, expression of p53 and downstream targets increased and cell growth was inhibited indicating an intact p14<sup>ARF</sup>-p53 axis. To investigate the discrepancy between <it>p14<sup>ARF </sup></it>mRNA and protein in retinoblastoma, we examined p14<sup>ARF </sup>biogenesis. The proteasome inhibitor, MG132, did not cause p14<sup>ARF </sup>accumulation, although p14<sup>ARF </sup>normally is degraded by proteasomes. miR-24, a microRNA that represses p14<sup>ARF </sup>expression, is expressed in retinoblastoma cell lines and correlates with lower protein expression when compared to other cell lines with high <it>p14<sup>ARF </sup></it>mRNA. Transient over-expression of siRNA against miR-24 led to elevated p14<sup>ARF </sup>protein in retinoblastoma cells.</p> <p>Conclusions</p> <p>In retinoblastoma cells where high levels of <it>p14<sup>ARF </sup></it>mRNA are not accompanied by high p14<sup>ARF </sup>protein, we found a correlation between miR-24 expression and low p14<sup>ARF </sup>protein. p14<sup>ARF </sup>protein levels were restored without change in mRNA abundance upon miR-24 inhibition suggesting that miR-24 could functionally repress expression, effectively blocking p53 tumor surveillance. During retinal tumorigenesis, miR-24 may intrinsically compromise the p53 response to <it>RB1 </it>loss.</p>
ISSN:1471-2407